Skip to main content
. Author manuscript; available in PMC: 2015 Jun 2.
Published in final edited form as: Cancer Cell. 2006 Jul;10(1):39–50. doi: 10.1016/j.ccr.2006.05.024

Figure 6.

Figure 6

INCB3619 induces apoptosis in A549 cells and has antitumor activity in the A549 xenograft model

A: INCB3619 can increase apoptosis and reduce the apoptotic threshold for paclitaxel in A549. Shown are the mean percentages of apoptosis with error bars (SD; n = 3).

B: The effect of INCB3619 on the growth of A549 human NSCLC xenograft in BALB/c nu/nu mice. INCB3619 was administered subcutaneously using ALZET osmotic pumps at 30 or 60 mg/kg/day for 14 days. The experiment has been repeated twice, and one set of data is shown here. Shown are mean tumor volumes with error bars (SEM; n = 7).

C: Combination effect of INCB3619 and paclitaxel in treatment of A549 human NSCLC xenografts in CD-1 nu/nu mice. INCB3619 was administered subcutaneously using ALZET osmotic pumps at a dose of 50 mg/kg/day for 14 days. Paclitaxel was administered intravenously at a dose of 20 mg/kg, every 4 days for a total of four injections. Shown are mean tumor volumes with error bars (SEM; n = 7).